Evidence map›Paper›PMID 34623194›Full record

ArticleTherapeutic advances in respiratory disease

Severe COVID-19 among patients with asthma and COPD: a report from the Swedish National Airway Register.

Johanna Karlsson Sundbaum, Lowie E G W Vanfleteren, Jon R Konradsen, Fredrik Nyberg, Ann Ekberg-Jansson, Caroline Stridsman

Abstract read
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hospital Admission Rates in Patients with COPD Throughout the COVID-19 Pandemic.International journal of chronic obstructive pulmonary disease · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Johanna Karlsson SundbaumDepartment of Health, Education and Technology, Luleå University of Technology, Luleå Tekniska universitet, 871 87 Luleå, Sweden.ORCID 0000-0001-5313-7981
Lowie E G W VanfleterenCOPD Center, Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Jon R KonradsenDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Fredrik NybergSchool of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Ann Ekberg-JanssonDepartment of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Caroline StridsmanThe OLIN-unit, Division of Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0001-6622-3838

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with obstructive lung diseases may be at risk of hospitalization and/or death due to COVID-19.

aimTo estimate the frequency of severe COVID-19, and COVID-19-related mortality in a well-defined large population of patients with asthma and chronic inflammatory lung disease (COPD). Further to assess the frequency of asthma and COPD as registered comorbidities at discharge from hospital, and in death certificates.

methodsAt the start of the pandemic, the Swedish National Airway Register (SNAR) included 271,404 patients with a physician diagnosis of asthma and/or COPD. In September 2020, after the first COVID-19 wave in Sweden, the database was linked with the National Patient Register (NPR), the Swedish Intensive Care Register and the Swedish Cause of Death Register, which all provide data about COVID-19 based on International Classification of Diseases (ICD-10) codes. Severe COVID-19 was defined as hospitalization and/or intensive care or death due to COVID-19.

resultsAmong patients in SNAR, 0.5% with asthma, and 1.2% with COPD were identified with severe COVID-19. Among patients  < 18 years with asthma, only 0.02% were severely infected. Of hospitalized adults, 14% with asthma and 29% with COPD died. Further, of patients in SNAR, 56% with asthma and 81% with COPD were also registered in the NPR, while on death certificates the agreement was lower (asthma 24% and COPD 71%).

conclusionThe frequency of severe COVID-19 in asthma and COPD was relative low. Mortality for those hospitalized was double as high in COPD compared to asthma. Comorbid asthma and COPD were not always identified among patients with severe COVID-19.

Indexed as

HospitalizationAdolescentAdultAgedAged, 80 and overAsthmaCOVID-19Databases, FactualFemaleHumansIntensive Care UnitsMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRegistriesSeverity of Illness IndexasthmaCOPDCOVID-19death certificateshospitalizationobstructive lung diseasesquality registerregister studies

Identifiers

PMID34623194
PMCPMC8512278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.